High-Sensitivity C-Reactive Protein (hs-CRP): What Inflammation Says About Your Heart Risk

C-reactive protein is made by the liver in response to interleukin-6, an inflammatory signaling molecule. CRP rises within hours of acute inflammation and falls back over days. The "high-sensitivity" assay measures CRP down to fractions of a mg/L — concentrations far below what a regular CRP test reports.

For cardiovascular risk assessment, only the high-sensitivity assay is useful. Asking for "CRP" instead of "hs-CRP" usually returns a result that is either undetectable (in someone with no acute illness) or wildly elevated (in someone with one). Neither version is informative for chronic risk.

What hs-CRP captures is hard to pin to a single tissue or process. It tracks closely with metabolic syndrome, visceral adiposity, periodontal disease, autoimmune activity, and chronic low-grade infections. In cardiology it is interpreted as a general index of vascular inflammation — the kind that promotes plaque instability.

The standard cardiovascular risk categories from the AHA and CDC:

• Below 1.0 mg/L: low cardiovascular risk.
• 1.0–3.0 mg/L: average to moderate cardiovascular risk.
• Above 3.0 mg/L: high cardiovascular risk.
• Above 10 mg/L: almost certainly acute inflammation, infection, or recent injury — defer interpretation, repeat in 2–4 weeks.

These categories assume the test was drawn outside of any acute illness. Even a mild cold can push hs-CRP into double digits temporarily.

An hs-CRP between 3 and 10 mg/L typically reflects chronic low-grade inflammation rather than active illness. Common drivers:

• Visceral obesity and metabolic syndrome. The single most common cause of mildly elevated hs-CRP. Adipose tissue, especially central fat, secretes inflammatory cytokines.
• Insulin resistance and type 2 diabetes.
• Smoking. Active smokers run hs-CRP roughly twice as high as non-smokers.
• Periodontal disease. An underrated source of chronic systemic inflammation.
• Autoimmune disease. Rheumatoid arthritis, lupus, psoriasis, ankylosing spondylitis — even quiescent disease can keep hs-CRP elevated.
• Chronic infections. Untreated dental abscesses, chronic sinusitis, hepatitis.
• Sleep apnea. Untreated OSA is a recognized cause of low-grade systemic inflammation.
• Estrogen. Both pregnancy and oral estrogens raise hs-CRP — interpret cautiously in those settings.
• Recent intense exercise. A marathon or long workout 24–72 hours before the draw can transiently raise hs-CRP.

The right way to interpret a single high hs-CRP: repeat it in 2–4 weeks, ideally without any acute illness in the prior month. About 50% of single elevated readings come down on a repeat test. Two consistent elevated readings are far more meaningful than one.

What lowers hs-CRP:

• Weight loss, especially visceral fat reduction (each 5 kg of weight loss drops hs-CRP by roughly 0.5–1.0 mg/L).
• Stopping smoking — most of the effect within 3–6 months.
• Aerobic exercise — modest but reliable.
• Statins — drop hs-CRP by 15–25% on top of their LDL effect.
• Treating periodontal disease.
• Treating sleep apnea.
• The Mediterranean diet — well-replicated 20–30% reductions in hs-CRP over 6–12 months.

Below 1.0 mg/L is favorable. There is no clinically meaningful "too low" hs-CRP — values below 0.3 are simply at the assay floor and reflect no detectable systemic inflammation. No action needed.

hs-CRP has high biological variability — repeat measurements in the same person can differ by 30–50% even without any change in health. This is partly assay variability, partly genuine biological fluctuation tied to recent illness, sleep, exercise, and stress.

For clinical decisions, the AHA recommendation is two readings on separate days at least 2 weeks apart, both in the absence of acute illness. The lower of the two values is generally taken as the patient's baseline. A single high reading without follow-up is a flag, not a diagnosis.

Once you have a stable baseline, the trend over years is the useful signal:

• A baseline that creeps from 1.0 to 3.0 over several years suggests accumulating metabolic disease.
• A baseline that drops from 4.0 to 1.5 after weight loss and exercise reflects real cardiovascular benefit.
• An hs-CRP that suddenly jumps from a stable 2.0 to 8.0 should prompt a search for an explanation — recent illness, new autoimmune flare, untreated dental issue, or a process worth investigating.

• hs-CRP above 10 mg/L — almost always acute. Defer interpretation, look for the source (infection, injury, autoimmune flare), and recheck in 2–4 weeks.
• hs-CRP above 3 mg/L on two separate readings, no acute illness — chronic inflammation worth addressing. Review weight, smoking, dental health, sleep apnea, and consider statin therapy if other cardiovascular risk factors are present.
• hs-CRP between 1 and 3 mg/L with borderline LDL — many cardiologists use this combination to tip toward earlier statin initiation, particularly in moderate-risk patients.
• Persistent low-grade elevation despite weight loss and lifestyle changes — consider an autoimmune workup, dental evaluation, sleep study, and review of medications.

• LDL Cholesterol — hs-CRP and LDL are independent risk axes; both matter. The JUPITER trial established that statins benefit patients with high hs-CRP even when LDL is not particularly high.
• Apolipoprotein B — atherogenic particle count.
• Lipoprotein(a) — genetic risk factor; complements hs-CRP.
• HbA1c and fasting glucose — visceral adiposity and insulin resistance drive most chronic hs-CRP elevation.
• ESR (erythrocyte sedimentation rate) — older, less specific inflammation marker; useful when autoimmune disease is being considered.
• Ferritin — also an acute-phase reactant; interpret iron studies cautiously when hs-CRP is elevated.